Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(1):14–22. doi: 10.1054/bjoc.2001.1892

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

D Choma 1, J-P Daurès 2, X Quantin 1, J L Pujol 1,2
PMCID: PMC2363907  PMID: 11437396

Abstract

In lung cancer, DNA content abnormalities have been described as a heterogeneous spectrum of impaired tumour cell DNA histogram patterns. They are merged into the common term of aneuploidy and probably reflect a high genotypic instability. In non-small-cell lung cancer, the negative effect of aneuploidy has been a subject of controversy inasmuch as studies aimed at determining the survival–DNA content relationship have reported conflicting results. We made a meta-analysis of published studies aimed at determining the prognostic effect of aneuploidy in surgically resected non-small-cell lung cancer. 35 trials have been identified in the literature. A comprehensive collection of data has been constructed taking into account the following parameters: quality of specimen, DNA content assessment method, aneuploidy definition, histology and stage grouping, quality of surgical resection and demographic characteristics of the analysed population. Among the 4033 assessable patients, 2626 suffered from non-small-cell lung cancer with aneuploid DNA content (overall frequency of aneuploidy: 0.65; 95% CI: (0.64–0.67)). The DerSimonian and Laird method was used to estimate the size effects and the Peto and Yusuf method was used in order to generate the odds ratios (OR) of reduction in risk of death for patients affected by a nearly diploid (non-aneuploid) non-small-cell lung cancer. Survivals following surgical resection, from 1 to 5 years, were chosen as the end-points of our meta-analysis. Patients suffering from a nearly diploid tumour benefited from a significant reduction in risk of death at 1, 2, 3 and 4 years with respective OR: 0.51, 0.51, 0.45 and 0.67 (P< 10−4for each end-point). 5 years after resection, the reduction of death was of lesser magnitude: OR: 0.87 (P = 0.08). The test for overall statistical heterogeneity was conventionally significant (P< 0.01) for all 5 end-points, however. None of the recorded characteristics of the studies could explain this phenomenon precluding a subset analysis. Therefore, the DerSimonian and Laird method was applied inasmuch as this method allows a correction for heterogeneity. This method demonstrated an increase in survival at 1, 2, 3, 4 and 5 years for patients with diploid tumours with respective size effects of 0.11, 0.15, 0.20, 0.20 and 0.21 (value taking into account the correction for heterogeneity;P< 10−4for each end-point). Patients who benefit from a surgical resection for non-small-cell lung cancer with aneuploid DNA content prove to have a higher risk of death. This negative prognostic factor decreases the probability of survival by 11% at one year, a negative effect deteriorating up to 21% at 5 years following surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ploidy, non-small-cell lung cancer, prognosis

Full Text

The Full Text of this article is available as a PDF (428.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asamura H., Ando M., Matsuno Y., Shimosato Y. Histopathologic prognostic factors in resected adenocarcinomas: is nuclear DNA content prognostic? Chest. 1999 Apr;115(4):1018–1024. doi: 10.1378/chest.115.4.1018. [DOI] [PubMed] [Google Scholar]
  2. Auer G., Eriksson E., Azavedo E., Caspersson T., Wallgren A. Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res. 1984 Jan;44(1):394–396. [PubMed] [Google Scholar]
  3. Barlogie B., Drewinko B., Schumann J., Göhde W., Dosik G., Latreille J., Johnston D. A., Freireich E. J. Cellular DNA content as a marker of neoplasia in man. Am J Med. 1980 Aug;69(2):195–203. doi: 10.1016/0002-9343(80)90379-4. [DOI] [PubMed] [Google Scholar]
  4. Barlogie B., Raber M. N., Schumann J., Johnson T. S., Drewinko B., Swartzendruber D. E., Göhde W., Andreeff M., Freireich E. J. Flow cytometry in clinical cancer research. Cancer Res. 1983 Sep;43(9):3982–3997. [PubMed] [Google Scholar]
  5. Bernardi F. D., Antonângelo L., Beyruti R., Takagaki T., Saldiva P. H., Capelozzi V. L. A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic, and biologic markers. Mod Pathol. 1997 Oct;10(10):992–1000. [PubMed] [Google Scholar]
  6. Blöndal T., Bengtsson A. Nuclear DNA measurements in squamous cell carcinoma of the lung: a guide for prognostic evaluation. Anticancer Res. 1981;1(2):79–86. [PubMed] [Google Scholar]
  7. Bondeson L., Azavedo E., Bondeson A. G., Caspersson T., Ljungberg O. Nuclear DNA content and behavior of oxyphil thyroid tumors. Cancer. 1986 Aug 1;58(3):672–675. doi: 10.1002/1097-0142(19860801)58:3<672::aid-cncr2820580312>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Bunn P. A., Jr, Carney D. N., Gazdar A. F., Whang-Peng J., Matthews M. J. Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer. Cancer Res. 1983 Oct;43(10):5026–5032. [PubMed] [Google Scholar]
  9. Carp N. Z., Ellison D. D., Brophy P. F., Watts P., Chang M. C., Keller S. M. DNA content in correlation with postsurgical stage in non-small cell lung cancer. Ann Thorac Surg. 1992 Apr;53(4):680–683. doi: 10.1016/0003-4975(92)90333-y. [DOI] [PubMed] [Google Scholar]
  10. Casson A. G., McCuaig S., Craig I., Ayed A., Inculet R., Kerkvliet N., O'Malley F. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J Surg Oncol. 1994 May;56(1):13–20. doi: 10.1002/jso.2930560105. [DOI] [PubMed] [Google Scholar]
  11. Cheon S. H., Sohn H. Y., Chang J., Kim S. K., Ko E. H., Kim S. K., Lee W. Y., Lee D. Y., Shin D. H., Jeong E. T. Flow cytometric analysis of DNA ploidy in primary non-small cell carcinoma of the lung in Korea. Yonsei Med J. 1993 Dec;34(4):365–370. doi: 10.3349/ymj.1993.34.4.365. [DOI] [PubMed] [Google Scholar]
  12. Chiba W., Sawai S., Hanawa T., Ishida H., Matsui T., Kosaba S., Watanabe S., Hatakenaka R., Matsubara Y., Funatsu T. [Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer]. Gan To Kagaku Ryoho. 1993 Apr;20(6):824–827. [PubMed] [Google Scholar]
  13. Cibas E. S., Melamed M. R., Zaman M. B., Kimmel M. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer. 1989 Apr 15;63(8):1552–1556. doi: 10.1002/1097-0142(19890415)63:8<1552::aid-cncr2820630817>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  14. Costa A., Silvestrini R., Mochen C., Lequaglie C., Boracchi P., Faranda A., Vessecchia G., Ravasi G. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer. 1996 Apr;73(7):914–919. doi: 10.1038/bjc.1996.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Coulson P. B., Thornthwaite J. T., Woolley T. W., Sugarbaker E. V., Seckinger D. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res. 1984 Sep;44(9):4187–4196. [PubMed] [Google Scholar]
  16. Dalquen P., Moch H., Feichter G., Lehmann M., Solèr M., Stulz P., Jordan P., Torhorst J., Mihatsch M. J., Sauter G. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch. 1997 Sep;431(3):173–179. doi: 10.1007/s004280050085. [DOI] [PubMed] [Google Scholar]
  17. Dazzi H., Thatcher N., Hasleton P. S., Swindell R. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med. 1990 May;84(3):217–223. doi: 10.1016/s0954-6111(08)80038-8. [DOI] [PubMed] [Google Scholar]
  18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  19. Filderman A. E., Silvestri G. A., Gatsonis C., Luthringer D. J., Honig J., Flynn S. D. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis. 1992 Sep;146(3):707–710. doi: 10.1164/ajrccm/146.3.707. [DOI] [PubMed] [Google Scholar]
  20. Friedlander M. L., Hedley D. W., Taylor I. W. Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol. 1984 Sep;37(9):961–974. doi: 10.1136/jcp.37.9.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Friedlander M. L., Hedley D. W., Taylor I. W., Russell P., Coates A. S., Tattersall M. H. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res. 1984 Jan;44(1):397–400. [PubMed] [Google Scholar]
  22. Granone P., Cardillo G., Rumi E., D'Ugo D., Rumi C., Ciletti S., Margaritora S., Terribile D., Picciocchi A. DNA flow cytometric analysis in patients with operable non-small cell lung carcinoma. Eur J Cardiothorac Surg. 1993;7(7):351–355. doi: 10.1016/1010-7940(93)90065-j. [DOI] [PubMed] [Google Scholar]
  23. Graziano S. L., Tatum A. H., Gonchoroff N. J., Newman N. B., Kohman L. J. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res. 1997 Jan;3(1):87–93. [PubMed] [Google Scholar]
  24. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  25. Huang M. S., Colby T. V., Therneau T. M., Daly R. C., Gonchoroff N. J. DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. Cytometry. 1996 Dec 15;26(4):253–259. doi: 10.1002/(SICI)1097-0320(19961215)26:4<253::AID-CYTO3>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  26. Ichinose Y., Hara N., Ohta M., Motohiro A., Kuda T., Aso H. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. J Surg Oncol. 1991 Jan;46(1):15–20. doi: 10.1002/jso.2930460105. [DOI] [PubMed] [Google Scholar]
  27. Ichinose Y., Hara N., Ohta M., Yano T., Maeda K., Asoh H., Katsuda Y. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg. 1993 Jul;106(1):90–94. [PubMed] [Google Scholar]
  28. Ikeda N., MacAulay C., Lam S., Garner D. M., Payne P. W., Kato H., Konaka C., Palcic B. Use of high-resolution cytometry in predicting the biologic behavior of T1 adenocarcinoma of the lung. Anal Quant Cytol Histol. 1995 Feb;17(1):69–74. [PubMed] [Google Scholar]
  29. Isobe H., Miyamoto H., Shimizu T., Haneda H., Hashimoto M., Inoue K., Mizuno S., Kawakami Y. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer. 1990 Mar 15;65(6):1391–1395. doi: 10.1002/1097-0142(19900315)65:6<1391::aid-cncr2820650624>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  30. Jeanfaivre T., Chassevent A., Geslin J., Larra F., Tuchais E. Valeur pronostique de la cytométrie en flux dans les cancers bronchiques épidermoïdes. Etude rétrospective à propos de 61 cas. Bull Cancer. 1997 Jun;84(6):597–602. [PubMed] [Google Scholar]
  31. Kolodziejski L., Niezabitowski A., Gasińska A. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer. 1997 Mar;16(2-3):173–182. doi: 10.1016/s0169-5002(96)00626-5. [DOI] [PubMed] [Google Scholar]
  32. Latreille J., Barlogie B., Dosik G., Johnston D. A., Drewinko B., Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood. 1980 Mar;55(3):403–408. [PubMed] [Google Scholar]
  33. Liewald F., Hatz R., Storck M., Orend K. H., Weiss M., Wulf G., Valet G., Sunder-Plassmann L. Prognostic value of deoxyribonucleic acid aneuploidy in primary non-small-cell lung carcinomas and their metastases. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1476–1482. [PubMed] [Google Scholar]
  34. Lima C., Matsui K., Kitagawa M., Mizushima Y., Noto H., Miwa A. Analysis of prognostic factors in patients with resected peripheral T1 adenocarcinoma of the lung. Pathol Res Pract. 1993 Dec;189(10):1149–1153. doi: 10.1016/S0344-0338(11)80837-X. [DOI] [PubMed] [Google Scholar]
  35. Matsuura H., Sugimachi K., Ueo H., Kuwano H., Koga Y., Okamura T. Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA analysis. Cancer. 1986 May 1;57(9):1810–1814. doi: 10.1002/1097-0142(19860501)57:9<1810::aid-cncr2820570917>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  36. Miyamoto H., Harada M., Isobe H., Akita H. D., Haneda H., Yamaguchi E., Kuzumaki N., Kawakami Y. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res. 1991 Dec 1;51(23 Pt 1):6346–6350. [PubMed] [Google Scholar]
  37. Mizumoto T., Tokui T., Kusagawa H., Sato T., Wada K., Den T., Kimura M., Namikawa S., Kusagawa M. [DNA analysis of resected pulmonary adenocarcinoma]. Nihon Kyobu Geka Gakkai Zasshi. 1991 Oct;39(10):1870–1875. [PubMed] [Google Scholar]
  38. Mugüerza J. M., Díez M., Torres A. J., López-Asenjo J. A., Picardo A. L., Gómez A., Hernando F., Cayón R., Granell J., Balibrea J. L. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: rationale of sequential processing of frozen and paraffin-embedded tissue. World J Surg. 1997 Mar-Apr;21(3):323–329. doi: 10.1007/s002689900237. [DOI] [PubMed] [Google Scholar]
  39. Mørkve O., Halvorsen O. J., Skjaerven R., Stangeland L., Gulsvik A., Laerum O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res. 1993 May-Jun;13(3):571–578. [PubMed] [Google Scholar]
  40. Nagai S., Chiba W., Ikeda S., Matsumoto H., Fujimoto T., Ishida H., Wazawa H., Hanawa T., Yamashita N., Yasuda Y. [Flow cytometric analysis of the DNA content of resected non-small cell lung cancer with reference to long-term follow-up]. Gan To Kagaku Ryoho. 1996 Jun;23 (Suppl 2):130–134. [PubMed] [Google Scholar]
  41. Nicolson G. L. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 1987 Mar 15;47(6):1473–1487. [PubMed] [Google Scholar]
  42. Ogawa J., Iwazaki M., Tsurumi T., Inoue H., Shohtsu A. Prognostic implications of DNA histogram, DNA content, and histologic changes of regional lymph nodes in patients with lung cancer. Cancer. 1991 Mar 1;67(5):1370–1376. doi: 10.1002/1097-0142(19910301)67:5<1370::aid-cncr2820670516>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  43. Ogawa J., Tsurumi T., Inoue H., Shohtsu A. Relationship between tumor DNA ploidy and regional lymph node changes in lung cancer. Cancer. 1992 Apr 1;69(7):1688–1695. doi: 10.1002/1097-0142(19920401)69:7<1688::aid-cncr2820690708>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  44. Oud P. S., Pahlplatz M. M., Beck J. L., Wiersma-Van Tilburg A., Wagenaar S. J., Vooijs G. P. Image and flow DNA cytometry of small cell carcinoma of the lung. Cancer. 1989 Sep 15;64(6):1304–1309. doi: 10.1002/1097-0142(19890915)64:6<1304::aid-cncr2820640623>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  45. Pence J. C., Kerns B. J., Dodge R. K., Iglehart J. D. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg. 1993 Dec;128(12):1382–1390. doi: 10.1001/archsurg.1993.01420240090017. [DOI] [PubMed] [Google Scholar]
  46. Pujol J. L., Simony J., Jolimoy G., Jaffuel D., Demoly P., Quantin X., Marty-Ané C., Boher J. M., Charpentier R., Michel F. B. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer. 1996 Sep;74(6):964–970. doi: 10.1038/bjc.1996.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rice T. W., Bauer T. W., Gephardt G. N., Medendorp S. V., McLain D. A., Kirby T. J. Prognostic significance of flow cytometry in non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1993 Aug;106(2):210–217. [PubMed] [Google Scholar]
  48. Roberts H. L., Komaki R., Allen P., El-Naggar A. K. Prognostic significance of DNA content in stage I adenocarcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):573–578. doi: 10.1016/s0360-3016(98)00099-6. [DOI] [PubMed] [Google Scholar]
  49. Sahin A. A., Ro J. Y., el-Naggar A. K., Lee J. S., Ayala A. G., Teague K., Hong W. K. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer. 1990 Feb 1;65(3):530–537. doi: 10.1002/1097-0142(19900201)65:3<530::aid-cncr2820650325>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  50. Salvati F., Teodori L., Gagliardi L., Signora M., Aquilini M., Storniello G. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications. Chest. 1989 Nov;96(5):1092–1098. doi: 10.1378/chest.96.5.1092. [DOI] [PubMed] [Google Scholar]
  51. Salvati F., Teodori L., Trinca M. L., Pasquali-Lasagni R., Göhde W. The relevance of flow-cytometric DNA content in the evaluation of lung cancer. J Cancer Res Clin Oncol. 1994;120(4):233–239. doi: 10.1007/BF01372562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sara A., el-Naggar A. K. Intratumoral DNA content variability. A study of non-small cell lung cancer. Am J Clin Pathol. 1991 Sep;96(3):311–317. doi: 10.1093/ajcp/96.3.311. [DOI] [PubMed] [Google Scholar]
  53. Shimizu J., Watanabe Y., Oda M., Hayashi Y., Ota Y., Morita K., Arano Y. [Results of surgical treatment of stage I lung cancer]. Nihon Geka Gakkai Zasshi. 1993 May;94(5):505–510. [PubMed] [Google Scholar]
  54. Shiota T., Konishi T., Kosaba S., Mitsuoka A., Matsubara Y., Hatakenaka R., Funatsu T., Ikeda S., Matsumoto H., Ishigami F. [Flow cytometric analysis of cellular DNA content of lung cancer with reference to survival]. Nihon Kyobu Geka Gakkai Zasshi. 1990 Dec;38(12):2364–2369. [PubMed] [Google Scholar]
  55. Simony J., Pujol J. L., Radal M., Ursule E., Michel F. B., Pujol H. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res. 1990 Jul 15;50(14):4382–4387. [PubMed] [Google Scholar]
  56. Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am J Med. 1986 May;80(5):841–843. doi: 10.1016/0002-9343(86)90625-x. [DOI] [PubMed] [Google Scholar]
  57. Stewart L. A., Parmar M. K. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993 Feb 13;341(8842):418–422. doi: 10.1016/0140-6736(93)93004-k. [DOI] [PubMed] [Google Scholar]
  58. Stipa S., Danesi D. T., Modini C., Cicconetti F., Mauro F., Schillaci A., Mecozzi A., Nicolanti V., Stipa F., Mancini M. The importance of heterogeneity and of multiple site sampling in the prospective determination of deoxyribonucleic acid flow cytometry. Surg Gynecol Obstet. 1993 May;176(5):427–434. [PubMed] [Google Scholar]
  59. Tanaka I., Masuda R., Furuhata Y., Inoue M., Fujiwara M., Takemura T. Flow cytometric analysis of the DNA content of adenocarcinoma of the lung, especially for patients with stage 1 disease with long term follow-up. Cancer. 1995 May 15;75(10):2461–2465. doi: 10.1002/1097-0142(19950515)75:10<2461::aid-cncr2820751011>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  60. Tirindelli-Danesi D., Teodori L., Mauro F., Modini C., Botti C., Cicconetti F., Stipa S. Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer. 1987 Aug 15;60(4):844–851. doi: 10.1002/1097-0142(19870815)60:4<844::aid-cncr2820600421>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  61. Usuda K., Saito Y., Aikawa H., Sakurada A., Chen Y., Takahashi S., Kanma K., Sato M., Sagawa M., Fujimura S. [Flow cytometric analysis of nuclear DNA content of lung cancer--correlation between nuclear DNA content and tumor doubling time]. Nihon Kyobu Geka Gakkai Zasshi. 1994 Apr;42(4):486–491. [PubMed] [Google Scholar]
  62. Visakorpi T., Holli K., Hakama M. High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma. Acta Oncol. 1995;34(5):605–609. doi: 10.3109/02841869509094035. [DOI] [PubMed] [Google Scholar]
  63. Volm M., Bak M., Hahn E. W., Mattern J., Weber E. DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma. Cytometry. 1988 Mar;9(2):183–188. doi: 10.1002/cyto.990090214. [DOI] [PubMed] [Google Scholar]
  64. Volm M., Hahn E. W., Mattern J., Müller T., Vogt-Moykopf I., Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 1988 May 15;48(10):2923–2928. [PubMed] [Google Scholar]
  65. Wolley R. C., Schreiber K., Koss L. G., Karas M., Sherman A. DNA distribution in human colon carcinomas and its relationship to clinical behavior. J Natl Cancer Inst. 1982 Jul;69(1):15–22. [PubMed] [Google Scholar]
  66. Yamaoka N., Uchiyama Y., Kimino K., Akamine S., Matsuo S., Tsuji K. [The prognostic significance of nuclear DNA content in non-small-cell lung carcinoma]. Nihon Geka Gakkai Zasshi. 1990 Oct;91(10):1608–1616. [PubMed] [Google Scholar]
  67. Yu J., Shaeffer J., Zhu A., Kuban D. A., el-Mahdi A. M., Philput C. B. Flow cytometric DNA content and clinical outcome in patients with non-small cell lung cancer given postoperative radiation therapy. Cytometry. 1993;14(4):428–432. doi: 10.1002/cyto.990140412. [DOI] [PubMed] [Google Scholar]
  68. Yusuf S., Collins R., Peto R., Furberg C., Stampfer M. J., Goldhaber S. Z., Hennekens C. H. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985 Jul;6(7):556–585. doi: 10.1093/oxfordjournals.eurheartj.a061905. [DOI] [PubMed] [Google Scholar]
  69. Zimmerman P. V., Hawson G. A., Bint M. H., Parsons P. G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet. 1987 Sep 5;2(8558):530–533. doi: 10.1016/s0140-6736(87)92923-0. [DOI] [PubMed] [Google Scholar]
  70. ten Velde G. P., Schutte B., Vermeulen A., Volovics A., Reynders M. M., Blijham G. H. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol. 1988 Mar;24(3):455–460. doi: 10.1016/s0277-5379(98)90016-5. [DOI] [PubMed] [Google Scholar]
  71. van Bodegom P. C., Baak J. P., Stroet-van Galen C., Schipper N. W., Wisse-Brekelmans E. C., Vanderschueren R. G., Wagenaar S. S. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long-term follow up. Cancer. 1989 Jan 1;63(1):143–147. doi: 10.1002/1097-0142(19890101)63:1<143::aid-cncr2820630123>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES